Purchase this article with an account.
H. Wafapoor, J. McCluskey; Intravitreal Ketorolac as a Treatment of Diabetic and Non–Diabetic Macular Edema . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4252.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the use of intravitreal ketorolac as an alternative to steroids in the treatment of macular edema.
Retrospective non–randomized case series. Inclusion criteria were a previous steroid response or diagnosis of glaucoma and no previous eye surgery within 3 months of intravitreal ketorolac injection and macular edema. Fluorescein angiography and optical coherence tomography were performed at baseline, 1 week, 1 month and 3 months. ETDRS visual acuity was performed at the same intervals.
Total of 7 eyes were reviewed with the following diagnosis: diabetic macular edema (4 eyes), chronic cystoid macular edema (2 eyes) and central retinal vein occlusion (CRVO) with macular edema ( 1 eye). Intravitreal ketorolac dosis was 60 mcg–90 mcg/0.1 ml in diabetic eyes, 200 mcg/0.1 ml in CME eyes and 900 mcg/0.1 ml in CRVO eye. Visual acuity improvement of 2 lines or more were seen in 2 diabetic eyes and 1 eye with CRVO and macular edema. The remainder of the eyes were stable. Complications such as cataract and increased intraocular pressure were not seen.
Intravitreal ketorolac may be considered as an alternative to steroids in selected patients. In this small pilot study no complications were observed.
This PDF is available to Subscribers Only